Another Denosumab Deal For mAbxience In MEA

MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets

View of Earth highlighting middle east and Africa
MS Pharma will market mAbxience’s denosumab in MEA territories • Source: Shutterstock

More from Deals

More from Business